DUBLIN--(BUSINESS WIRE)--Sep 6, 2018--The "Notch Signaling Pathway Inhibitor -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

'Notch Signaling Pathway Inhibitor - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Notch Signaling Pathway Inhibitor development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Descriptive coverage of pipeline development activities for Notch Signaling Pathway Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Key Topics Covered:

1. Report Introduction

2. Notch Signaling Pathway Inhibitor - Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Notch Signaling Pathway Inhibitor

4. Comparative Analysis

5. Notch Signaling Pathway Inhibitor Pipeline Products in Clinical StagesProduct DescriptionResearch and DevelopmentProduct Development Activities

6. Notch Signaling Pathway Inhibitor Pipeline Products in Non-clinical Stages

Product DescriptionResearch and DevelopmentProduct Development Activities

7. Therapeutic Assessment: Active Products

Pipeline Assessment by Route of AdministrationPipeline Assessment by Stage and Route of AdministrationPipeline Assessment by Molecule TypePipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

Product DescriptionResearch and DevelopmentProduct Development ActivitiesReason for dormancy/discontinuation

Companies Mentioned

Bristol-Myers SquibbEli LillyOncoMedUniversity of WisconsinMedImmuneMerck/ Cancer research UKPfizerRoche/ US National Cancer InstituteMerckInterprotein CorporationFor more information about this drug pipelines report visit https://www.researchandmarkets.com/research/znqqpw/notch_signaling?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180906005956/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/06/2018 05:09 PM/DISC: 09/06/2018 05:09 PM

http://www.businesswire.com/news/home/20180906005956/en